Regarding the clinical implications of our findings, the associations found provide valuable insights into the impact of non-DPYD variants, specifically CES1 rs71647871 and CDA s1048977, on the toxicity of capecitabine-based therapy in terms of the hand–foot syndrome (HFS) and treatment suspension due to toxicity. This evidence concerns the gene CDA and Hand-foot syndrome.